Sign Up to like & get
recommendations!
0
Published in 2019 at "Cancer"
DOI: 10.1002/cncr.32206
Abstract: Nivolumab demonstrated durable responses and safety in patients with hepatocellular carcinoma (HCC) with Child‐Pugh class A cirrhosis in the CheckMate 040 trial, with rates of hepatotoxicity that were similar to those of non‐HCC populations. To…
read more here.
Keywords:
hepatocellular carcinoma;
cirrhosis;
safety;
child pugh ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2018 at "Gastroenterology"
DOI: 10.1053/j.gastro.2018.04.008
Abstract: BACKGROUND & AIMS Studies have produced conflicting results of the incidence of hepatocellular carcinoma (HCC) in patients with hepatitis C virus-associated cirrhosis treated with direct-acting antivirals (DAAs). Data from clinics are needed to accurately assess…
read more here.
Keywords:
hcc;
cirrhosis;
associated cirrhosis;
child pugh ... See more keywords
Sign Up to like & get
recommendations!
3
Published in 2023 at "Clinical orthopaedics and related research"
DOI: 10.1097/corr.0000000000002631
Abstract: BACKGROUND Patients with hepatitis C virus (HCV) undergoing primary elective total joint arthroplasty (TJA) are at increased risk of postoperative complications. Patients with chronic liver disease and cirrhosis, specifically Child-Pugh Class B and C, who…
read more here.
Keywords:
disease;
pugh class;
mortality;
early mortality ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2021 at "Antibiotics"
DOI: 10.3390/antibiotics10091130
Abstract: This prospective observational study aimed to clinically describe voriconazole administrations and trough concentrations in patients with Child–Pugh class C and to investigate the variability of trough concentration. A total of 144 voriconazole trough concentrations from…
read more here.
Keywords:
trough concentrations;
patients child;
concentrations patients;
child pugh ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2023 at "International Journal of Molecular Sciences"
DOI: 10.3390/ijms24054543
Abstract: Hepatic drug metabolizing enzymes (DMEs), whose activity may be affected by liver diseases, are major determinants of drug pharmacokinetics. Hepatitis C liver samples in different functional states, i.e., the Child–Pugh class A (n = 30),…
read more here.
Keywords:
protein abundance;
pugh class;
drug metabolizing;
child pugh ... See more keywords